ABT250502P146000
- 14.50
- 0.000.00%
Abbott Laboratories Newsroom
TD Cowen Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $145
Abbott Laboratories: Strategic Advancements and Market Positioning With Volt PFA Platform Drive Buy Rating
Argus Research Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $150
Argus Research Reaffirms Their Buy Rating on Abbott Laboratories (ABT)
A Quick Look at Today's Ratings for Abbott Laboratories(ABT.US), With a Forecast Between $140 to $155
RBC Capital Maintains Outperform on Abbott Laboratories, Raises Price Target to $145
Abbott Labs Is Maintained at Overweight by Wells Fargo
Abbott Labs Is Maintained at Overweight by Barclays
Abbott Labs Is Maintained at Buy by Stifel
A Quick Look at Today's Ratings for Abbott Laboratories(ABT.US), With a Forecast Between $130 to $159
Abbott Laboratories Analyst Ratings
Jefferies Adjusts Price Target on Abbott Laboratories to $137 From $135, Keeps Hold Rating
TD Cowen Adjusts Price Target on Abbott Laboratories to $145 From $135, Keeps Buy Rating
BTIG Adjusts Price Target on Abbott Laboratories to $145 From $140, Keeps Buy Rating
Citi Reaffirms Their Buy Rating on Abbott Laboratories (ABT)
Morgan Stanley Raises Price Target on Abbott Laboratories to $127 From $117, Keeps Equalweight Rating
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Blueprint Medicines (BPMC)
Evercore ISI Adjusts Price Target on Abbott Laboratories to $140 From $138
Research Alert: Abbott Reports Solid Q1 Results With Strength In Medical Devices
RBC Capital Maintains Abbott Laboratories(ABT.US) With Buy Rating, Raises Target Price to $140